Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0151-9638(06)70900-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development.
PLoS One
January 2025
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
End-user feedback early in product development is important for optimizing multipurpose prevention technologies for HIV and pregnancy prevention. We evaluated the acceptability of the 90-day dapivirine levonorgestrel ring (DPV-LNG ring) used for 14 days compared to a dapivirine-only ring (DVR-200mg) in MTN-030/IPM 041 (n = 23), and when used for 90 days cyclically or continuously in MTN-044/IPM 053/CCN019 (n = 25). We enrolled healthy, non-pregnant, HIV-negative women aged 18-45 in Pittsburgh, PA and Birmingham, AL (MTN-030 only).
View Article and Find Full Text PDFLong-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
J Natl Cancer Inst
January 2025
School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia.
Background: Use of long-acting, reversible contraceptives has increased over the past 20 years, but an understanding of how they could influence cancer risk is limited.
Methods: We conducted a nested case-control study among a national cohort of Australian women (n = 176 601 diagnosed with cancer between 2004 and 2013; 882 999 matched control individuals) to investigate the associations between the levonorgestrel intrauterine system, etonogestrel implants, depot-medroxyprogesterone acetate and cancer risk and compared these results with the oral contraceptive pill. We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI).
Tumor Microenvironment Responsive Key Nanomicelles for Effective Against Invasion and Metastasis in Ovarian Cancer Using Mice Model.
Int J Nanomedicine
January 2025
School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, People's Republic of China.
Background: Ovarian cancer is difficult to detect in its early stages, and it has a high potential for invasion and metastasis, along with a high rate of recurrence. These factors contribute to the poor prognosis and reduced survival times for patients with this disease. The effectiveness of conventional chemoradiotherapy remains limited.
View Article and Find Full Text PDFUse of period- or fertility-tracking technologies pre- and post-Dobbs.
Contraception
January 2025
College of Public Health, The Ohio State University, 1841 Neil Ave, Columbus, OH 43210, USA. Electronic address:
Objective: This study aimed to evaluate whether use of period- or fertility-tracking technologies decreased from pre- to post-Dobbs, and to identify user characteristics and changes in reasons for use.
Study Design: We used data from the Surveys of Women, population-based surveys on reproductive health among self-identified women aged 18-44 years, conducted in five states. We compared prevalence of use of period- or fertility-tracking technologies and reasons for use pre-Dobbs (2018-2019 in Iowa and Ohio; 2019-2020 in Arizona, New Jersey, and Wisconsin) and post-Dobbs (2022-2023 in all five states), overall and stratified by state.
Validation of the Contraception-Focused Preference-Aligned Fertility Management Index in Uganda and Nigeria.
Contraception
January 2025
Bill & Melinda Gates Foundation, 500 5th Avenue N, Seattle, WA, 98109, USA.
Objective: To evaluate construct validity of the contraception-focused "Preference-aligned Fertility Management" (PFM) Index, a new person-centered and rights-based outcome measure, in Nigeria and Uganda.
Study Design: We analyzed survey data from convenience samples of new users of contraception and non-users of contraception in Uganda and users of contraception in Nigeria. PFM Index scores were calculated by combining two indicators: Indicator 1 assessing alignment between desire to use contraception and actual use; Indicator 2 evaluating whether users' current methods are desired.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!